Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이현주 | - |
dc.date.accessioned | 2018-03-16T03:02:00Z | - |
dc.date.available | 2018-03-16T03:02:00Z | - |
dc.date.issued | 2014-01 | - |
dc.identifier.citation | Yonsei Med J, 55, 1, 99-106 | en_US |
dc.identifier.issn | 0513-5796 | - |
dc.identifier.issn | 1976-2437 | - |
dc.identifier.uri | https://synapse.koreamed.org/search.php?where=aview&id=10.3349/ymj.2014.55.1.99&code=0069YMJ&vmode=FULL | - |
dc.identifier.uri | http://hdl.handle.net/20.500.11754/47736 | - |
dc.description.abstract | PurposeWe tested whether rosiglitazone (RGZ), a peroxisome proliferator-activated receptor-γ agonist, can restore alveolar development and vascular growth in a rat model of bronchopulmonary dysplasia (BPD).Materials and MethodsA rat model of BPD was induced through intra-amniotic delivery of lipopolysaccharide (LPS) and postnatal hyperoxia (80% for 7 days). RGZ (3 mg/kg/d, i.p.) or vehicle was given daily to rat pups for 14 days. This model included four experimental groups: No BPD+vehicle (V), No BPD+RGZ, BPD+V, and BPD+RGZ. On D14, alveolarization, lung vascular density, and right ventricular hypertrophy (RVH) were evaluated.ResultsMorphometric analysis revealed that the BPD+RGZ group had significantly smaller and more complex airspaces and larger alveolar surface area than the BPD+V group. The BPD+RGZ group had significantly greater pulmonary vascular density than the BPD+V group. Western blot analysis revealed that significantly decreased levels of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 by the combined exposure to intra-amniotic LPS and postnatal hyperoxia were restored by the RGZ treatment. RVH was significantly lesser in the BPD+RGZ group than in the BPD+V group.ConclusionThese results suggest that RGZ can restore alveolar and pulmonary vascular development and lessen pulmonary hypertension in a rat model of BPD. | en_US |
dc.description.sponsorship | This study was supported by a grant of the Basic Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2010-0021644) and by the SNUBH Research Fund (grant no. 02-2012-006). | en_US |
dc.language.iso | en | en_US |
dc.publisher | Yonsei University College of Medicine 2014 | en_US |
dc.subject | Bronchopulmonary dysplasi | en_US |
dc.subject | peroxisome proliferator-activated receptor-γ | en_US |
dc.subject | rosiglitazone | en_US |
dc.subject | alveolarization | en_US |
dc.title | Rosiglitazone, a Peroxisome Proliferator-Activated Receptor-gamma Agonist, Restores Alveolar and Pulmonary Vascular Development in a Rat Model of Bronchopulmonary Dysplasia | en_US |
dc.type | Article | en_US |
dc.relation.no | 1 | - |
dc.relation.volume | 55 | - |
dc.identifier.doi | 10.3349/ymj.2014.55.1.99 | - |
dc.relation.page | 99-106 | - |
dc.relation.journal | YONSEI MEDICAL JOURNAL | - |
dc.contributor.googleauthor | Lee, Hyun Ju | - |
dc.contributor.googleauthor | Lee, Youn Jin | - |
dc.contributor.googleauthor | Choi, Chang Won | - |
dc.contributor.googleauthor | Lee, Jin-A | - |
dc.contributor.googleauthor | Kim, Ee-Kyung | - |
dc.contributor.googleauthor | Kim, Han-Suk | - |
dc.contributor.googleauthor | Kim, Beyong Il | - |
dc.contributor.googleauthor | Choi, Jung-Hwan | - |
dc.relation.code | 2014041116 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | blesslee77 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.